TWI896097B - 含替格列汀製劑 - Google Patents

含替格列汀製劑

Info

Publication number
TWI896097B
TWI896097B TW113115272A TW113115272A TWI896097B TW I896097 B TWI896097 B TW I896097B TW 113115272 A TW113115272 A TW 113115272A TW 113115272 A TW113115272 A TW 113115272A TW I896097 B TWI896097 B TW I896097B
Authority
TW
Taiwan
Prior art keywords
tenegliptin
acid
amorphous
reference example
porous silica
Prior art date
Application number
TW113115272A
Other languages
English (en)
Chinese (zh)
Other versions
TW202444369A (zh
Inventor
西村卓朗
豊田晴大
Original Assignee
日商澤井製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商澤井製藥股份有限公司 filed Critical 日商澤井製藥股份有限公司
Publication of TW202444369A publication Critical patent/TW202444369A/zh
Application granted granted Critical
Publication of TWI896097B publication Critical patent/TWI896097B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW113115272A 2023-05-10 2024-04-24 含替格列汀製劑 TWI896097B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-078027 2023-05-10
JP2023078027 2023-05-10

Publications (2)

Publication Number Publication Date
TW202444369A TW202444369A (zh) 2024-11-16
TWI896097B true TWI896097B (zh) 2025-09-01

Family

ID=93430149

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113115272A TWI896097B (zh) 2023-05-10 2024-04-24 含替格列汀製劑

Country Status (4)

Country Link
JP (1) JP7799904B2 (https=)
CN (1) CN119300831A (https=)
TW (1) TWI896097B (https=)
WO (1) WO2024232216A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7117975B2 (ja) * 2018-10-31 2022-08-15 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
WO2020209350A1 (ja) 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
JP2023156269A (ja) 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Also Published As

Publication number Publication date
TW202444369A (zh) 2024-11-16
CN119300831A (zh) 2025-01-10
JPWO2024232216A1 (https=) 2024-11-14
JP7799904B2 (ja) 2026-01-15
WO2024232216A1 (ja) 2024-11-14

Similar Documents

Publication Publication Date Title
CN102006861B (zh) 口腔崩解片
CN102196811B (zh) 含有4,5-环氧基吗啡烷衍生物的稳定片剂
JP7117975B2 (ja) テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP6446511B2 (ja) 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤
EP2934488B1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
JP2016104812A (ja) ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤
US20210244732A1 (en) Packaging body of pharmaceutical composition containing antitumor agent
KR101469326B1 (ko) 베포타스틴 또는 이의 약학적으로 허용가능한 염과 수불용성 염기성 물질을 포함하는 약제학적 제제
TWI896097B (zh) 含替格列汀製劑
MX2007000632A (es) Composicion antihistaminica.
US10668069B2 (en) Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
JP7518316B1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
CN108135898A (zh) 稳定化的医药组合物
TW202432125A (zh) 含替格列汀粒子及包含其之製劑
ES2686704T3 (es) Formas de dosificación farmacéutica
WO2018079570A1 (ja) 安定な医薬組成物
EP4302755B1 (en) Palbociclib formulation containing an amino acid
JP6272328B2 (ja) カンデサルタンシレキセチル含有製剤
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
JPWO2007046411A1 (ja) イソキサゾール化合物の安定化方法
JP2020045323A (ja) コハク酸ソリフェナシン含有製剤
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
EP4140478A1 (en) A solid pharmaceutical composition comprising sacubitril and valsartan
JP2015193611A (ja) 安定な固形医薬組成物